SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?


To: Harold Engstrom who wrote (7287)1/15/2004 9:06:48 AM
From: Biomaven  Read Replies (1) | Respond to of 10280
 
From their website:

S)-Oxybutynin for the treatment of overactive bladder. Further clinical development of (S)-Oxybutynin is on hold pending further formulation development and review of the program.

Sounds like they have some issue here over-and-above limited financial resources.

IDEV's Trospium might be the beneficiary.

Peter